Asset
Zandatrigine
Xenon Pharmaceuticals Inc. Common Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03467100 | phase1 | completed | 2018-02-19 | 2018-12-19 | Xenon Pharmaceuticals Inc. | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 |
FDA applications (0)
This company has no applications containing this asset.